The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Scott Henry - ROTH Capital Partners - Analyst
: Thank you and good afternoon. Kirk, you covered a lot of ground there. Just a couple of questions.
First, with regards to VIPs, I recognize that the revenue will be spread over a larger time period, which will eventually annualize, and it will be similar.
But that VIP add number of 50 in fourth quarter, do you think that's a representative number of what you would expect to add quarterly going
forward? Or what types of adds should we be thinking about on a quarterly basis knowing there will be some volatility?
Question: Scott Henry - ROTH Capital Partners - Analyst
: Okay. And then appliances was kind of flat quarter-to-quarter sequentially third quarter to fourth quarter. How do you find utilization for dentist?
How should we think about that trend? Should we think about it flat or just with more dentists driving the number? Or do you think you'll get some
more gains as far as appliance per dentist?
Question: Scott Henry - ROTH Capital Partners - Analyst
: Okay. And then the acquisition that recently took place, how should we think about the magnitude of revenue gains there in the timeline of realizing
those revenue gains?
Question: Scott Henry - ROTH Capital Partners - Analyst
: Okay, great. Thank you for taking the questions.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Hi, guys. Good afternoon, and congratulations on your progress.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: So I wanted to ask about these institutional partnerships. You've got the DSOs and the DMEs, and it sounds like there's just massive business there.
So, I'm wondering like, what are the bottlenecks, like how long does it take to close these deals? And once you do get a major DSO or a DME on
board, does it just open the floodgates or is this something that we can model?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. I just had a couple of financial questions, possibly for Brad or whoever wants to take it.
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Can you say what your revenues in the fourth quarter would have been without the revenue recognition change? So instead of $4 million, would
it have been $5 million or higher?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. Clear. And then with respect to operating expenses, I was wondering if you could give a little color there. It looks like the sales and marketing
was up sequentially quite a bit, although you were down a little on G&A. I'm wondering sort of what the trend is likely to be for 2023 on -- well, just
operating expenses overall. So, you did $35 million this year, like do you expect that to grow in 2023? And if so, like roughly how much?
Question: Lucas Ward - Ascendiant Capital Markets - Analyst
: Okay. Clear. Thank you very much. These were all my questions.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MARCH 30, 2023 / 9:00PM, VVOS.OQ - Q4 2022 Vivos Therapeutics Inc Earnings Call
| 
